A Discussion with Michael Proschan on Response-Adaptive Randomization
In this episode of "In the Interim…", Dr. Scott Berry and NIH’s Dr. Michael Proschan conduct a detailed discussion from opposing viewpoints on response-adaptive randomization (RAR) in clinical trials. The discussion focuses on where they agree – on the positives and negatives of RAR, and where they disagree on its scientific use.
Key Highlights
- Potential issues of using RAR: Potential temporal trends, unblinding, reduction in statistical efficiency in 2-arm trials
- Potential benefits include improved statistical efficiency in multi-arm trials depending on the goals (e.g. dose-finding trials).
- Potential unblinding of results in non-blinded trials and the need for operational excellence.
- Ethical and Bayesian perspectives are considered, but emphasis remains empirical.
For more visit: https://www.berryconsultants.com/
2025-08-18
44 min
Transcript
Available Results
Generated results are saved to the knowledge database for reuse and search.
No generated results are available for this episode yet.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.
Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
Transcript
Chapters
No chapters available.